News by Tag: Us Biosimilar Market
Biosimilar Insulin Products in the US to Grow at a CAGR of 74 Percent over the Period 2013-2020
January 25, 2012
Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.
January 25, 2012
Lantus is expected to be the most lucrative target for biosimilar manufacturers and account for 71% of the total biosimilar Insulin sales by 2020.
The Market for Biosimilars Will be a Marathon and Not a Sprint
July 27, 2011
A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.
July 27, 2011
A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.